GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

The MHRA has approved depemokimab as an add on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...

In this video, Jonathan A. Bernstein, MD, discusses his American College of Allergy, Asthma & Immunology Annual Scientific ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Around 88% of primary care providers managing patients with uncontrolled asthma reported being unfamiliar or only somewhat ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

A monthly injection for managing severe asthma could help patients safely reduce or even discontinue daily steroid ...

Allergy shots and drops offer a transformative solution for millions. Major health organisations globally endorse this ...